N

NextCure
D

NXTC

0.72990
USD
-0.01
(-1.36%)
مغلق
حجم التداول
10
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
20,442,079
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    CHKP
    CHKP
    -2.170
    (-0.99%)
    216.890 USD
    CRWD
    CRWD
    -29.49
    (-6.76%)
    406.64 USD
    F
    FFIV
    -9.10
    (-2.99%)
    295.56 USD
    FTNT
    FTNT
    -4.165
    (-3.65%)
    110.035 USD
    PANW
    PANW
    -7.720
    (-3.88%)
    191.080 USD
    Q
    QLYS
    -3.250
    (-2.33%)
    136.160 USD
    V
    VRNT
    -0.970
    (-3.84%)
    24.310 USD
    ZS
    ZS
    -8.490
    (-4.10%)
    198.540 USD
    المزيد
الأخبار
المقالات

العنوان: NextCure

القطاع: Healthcare
الصناعة: Biotechnology
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.